MX2021005910A - Formulacion de proteina de alta concentracion. - Google Patents

Formulacion de proteina de alta concentracion.

Info

Publication number
MX2021005910A
MX2021005910A MX2021005910A MX2021005910A MX2021005910A MX 2021005910 A MX2021005910 A MX 2021005910A MX 2021005910 A MX2021005910 A MX 2021005910A MX 2021005910 A MX2021005910 A MX 2021005910A MX 2021005910 A MX2021005910 A MX 2021005910A
Authority
MX
Mexico
Prior art keywords
high concentration
protein formulation
concentration protein
formulation
compositions
Prior art date
Application number
MX2021005910A
Other languages
English (en)
Spanish (es)
Inventor
Hunter Chen
Erica Schlesinger
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2021005910A publication Critical patent/MX2021005910A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MX2021005910A 2018-11-21 2019-11-21 Formulacion de proteina de alta concentracion. MX2021005910A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862770337P 2018-11-21 2018-11-21
PCT/US2019/062596 WO2020106948A1 (en) 2018-11-21 2019-11-21 High concentration protein formulation

Publications (1)

Publication Number Publication Date
MX2021005910A true MX2021005910A (es) 2021-08-16

Family

ID=68916589

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021005910A MX2021005910A (es) 2018-11-21 2019-11-21 Formulacion de proteina de alta concentracion.

Country Status (14)

Country Link
US (2) US12036280B2 (cg-RX-API-DMAC7.html)
EP (1) EP3883542A1 (cg-RX-API-DMAC7.html)
JP (1) JP7637618B2 (cg-RX-API-DMAC7.html)
KR (1) KR102944691B1 (cg-RX-API-DMAC7.html)
CN (1) CN113164378A (cg-RX-API-DMAC7.html)
AU (1) AU2019384160B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021009463A2 (cg-RX-API-DMAC7.html)
CA (1) CA3118306A1 (cg-RX-API-DMAC7.html)
EA (1) EA202191403A1 (cg-RX-API-DMAC7.html)
IL (1) IL283229B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021005910A (cg-RX-API-DMAC7.html)
SG (1) SG11202104166QA (cg-RX-API-DMAC7.html)
WO (1) WO2020106948A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202102816B (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS67656B1 (sr) 2018-05-10 2026-02-27 Regeneron Pharma Formulacije koje sadrže visoke koncentracije fuzionog proteina vegf receptora
PE20212185A1 (es) 2019-02-18 2021-11-11 Lilly Co Eli Formulacion de anticuerpos terapeuticos
EP4398874A1 (en) * 2021-09-09 2024-07-17 Xeris Pharmaceuticals, Inc. Injectable high concentration pharmaceutical formulations and methods of manufacturing and use thereof
CN122070304A (zh) * 2023-08-24 2026-05-19 瑞泽乐特公司 用于抗胰岛素受体抗体的高浓度调配物和其用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1142172B (it) * 1978-10-19 1986-10-08 Sandoz Ag Nuovo impiego in terapeutica della ciclosporina-a e della diidrociclosporina-c
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
MXPA03001092A (es) * 2000-08-07 2003-09-25 Nektar Therapeutics Al Corp Polvos de proteina de haz de 4 helices secados por rocio, inhalables, que tienen agregacion minimizada.
US20090208492A1 (en) 2007-06-14 2009-08-20 Elan Pharmaceuticals, Inc. Lyophilized Immunoglobulin Formulations and Methods of Preparation
US20110223208A1 (en) 2010-03-09 2011-09-15 Beth Hill Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
US9072668B2 (en) * 2010-03-09 2015-07-07 Janssen Biotech, Inc. Non-aqueous high concentration reduced viscosity suspension formulations of antibodies
CA2829629A1 (en) * 2011-03-10 2012-09-13 Board Of Regents, The University Of Texas System Protein nanoparticle dispersions
CN103356490A (zh) * 2012-03-29 2013-10-23 复旦大学 可直接固体化的交联食物蛋白稳定化纳米给药系统
SI2849723T1 (sl) * 2012-05-18 2018-09-28 Genentech, Inc. Formulacije z visoko koncentracijo monoklonskih protiteles
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
IL312865B2 (en) * 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
SMT202200464T1 (it) * 2014-05-06 2023-01-13 S I I T S R L Servizio Int Imballaggi Termosaldanti Formulazione oleosa erogabile tramite spray a base di vitamine liposolubili del gruppo d e relativo uso
JP2018500380A (ja) 2014-12-31 2018-01-11 ノベルメド セラピューティクス,インコーポレーテッド アグリコシル化治療用抗体の製剤
JP7275027B2 (ja) * 2016-10-06 2023-05-17 アムジェン インコーポレイテッド 粘度低下タンパク質医薬製剤

Also Published As

Publication number Publication date
US20200155678A1 (en) 2020-05-21
BR112021009463A2 (pt) 2021-08-10
EP3883542A1 (en) 2021-09-29
WO2020106948A1 (en) 2020-05-28
US12036280B2 (en) 2024-07-16
ZA202102816B (en) 2024-08-28
SG11202104166QA (en) 2021-05-28
JP2022532965A (ja) 2022-07-21
KR20210093976A (ko) 2021-07-28
IL283229B2 (en) 2025-08-01
KR102944691B1 (ko) 2026-03-30
US20240316195A1 (en) 2024-09-26
IL283229B1 (en) 2025-04-01
CA3118306A1 (en) 2020-05-28
AU2019384160B2 (en) 2025-01-16
EA202191403A1 (ru) 2021-08-09
CN113164378A (zh) 2021-07-23
JP7637618B2 (ja) 2025-02-28
AU2019384160A1 (en) 2021-05-27
IL283229A (en) 2021-07-29

Similar Documents

Publication Publication Date Title
CO2019006291A2 (es) Composiciones de aminoácidos y métodos de tratamiento de enfermedades hepáticas
EA201891083A1 (ru) Составы антител к cd38 для подкожного введения и их применение
CL2018000320A1 (es) Coadyuvantes basados en aceite (divisional de solicitud 201600650)
AR100215A1 (es) Conjugados de anticuerpo-fármaco anti-ptk7
MX2017016655A (es) Formulaciones oftalmicas de inhibidores de tirosina quinasa, metodos de uso de las mismas y metodos de preparacion de las mismas.
BR112017023161A2 (pt) composições de ácido obeticólico e métodos de uso
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201790273A1 (ru) Флагеллиновые композиции и их применение
SA521421715B1 (ar) تركيبات سيماجلوتيد ثابتة واستخداماتها
CO2020005919A2 (es) Compuestos y composiciones farmaceuticas de los mismos para usarse en el tratamiento de enfermedades fibroticas
BR112017027721A2 (pt) formulação de alta concentração
DOP2021000170A (es) Formulacion de anticuerpos terapeuticos
EA201591752A1 (ru) Дипептидные и трипептидные эпоксикетонные ингибиторы протеазы
CL2019001053A1 (es) Formulaciones farmacéuticas y métodos para prepararlas.
CL2020002519A1 (es) Composiciones de erenumab y usos de las mismas
ZA202102816B (en) High concentration protein formulation
MX2019005925A (es) Composiciones de alergenos liquidas y metodos para la preparacion de las mismas.
MX387731B (es) Composiciones farmacéuticas orales de mesalazina.
JO3565B1 (ar) الأجسام المضادة لشبيه الأنجيوبوييتين– 4 وطرق استخدامها
JOP20200126B1 (ar) طرق استخدام وتركيبات تحتوي على دولاجلوتيد
MX2021003888A (es) Nuevos compuestos utiles para el tratamiento de enfermedades cardiovasculares.
EA202090666A1 (ru) Применение содержащей бензоат композиции для лечения глициновой энцефалопатии
EA201991319A1 (ru) Вакцины аттенуированного свиного гриппа и способы их изготовления и применения
BR112019017314A2 (pt) composições farmacêuticas para terapia de combinação
CL2018002848A1 (es) Formulaciones liquidas de fosfoplatino